Brought to you by 
PharmAthene, Theraclone agree to merge; deal terminated
27 Aug 2020
Executive Summary
Public biodefense firm PharmAthene Inc. and private antibody developer Theraclone Sciences Inc. have agreed to merge in a stock swap. PharmAthene issued Theraclone about 60.3mm common shares--worth $105.6mm based on 10-day average prior to deal announcement.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PharmAthene, Theraclone agree to merge; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice